To cast a spotlight on disruptive biotechnology stocks, Raghuram "Ram" Selvaraju of Aegis Capital Corp. taps his experience as a molecular biologist, preclinical investigator and
Keith Markey, veteran analyst and science director of Griffin Securities, tells us the 2014 pipeline calendar is positively glowing with important milestones that could ignite portfolios. In this
At www.ValuEngine.com we show that the Medical sector 13.6% overvalued with the medical Instruments industry 2.0% undervalued. All 12 stocks in today’s table have complete ValuEngine data and
A question I’ve noted in the media of late: With sentiment noticeably more positive these days, should we be worried about the bull market's imminent end?It's a valid question. Remember Sir John
